<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705429</url>
  </required_header>
  <id_info>
    <org_study_id>REaCT-Low Risk HER-2</org_study_id>
    <nct_id>NCT03705429</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer</brief_title>
  <official_title>A Multi-Centre Randomized Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will
      receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with
      trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved
      doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of
      life (QoL), patient reported outcomes and clinical benefits of the two treatment strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will
      receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with
      trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved
      doses. The primary objective is to estimate the feasibility of opening a pragmatic clinical
      trial with an Integrated Consent Model Secondary objectives are: Compare adverse events/
      toxicity profile between the two different approaches (i.e. neutropenia, peripheral
      neuropathy, treatment-related hospitalizations, proportion of patients completing the
      chemotherapy component of their treatment); Estimate the cost of each chemotherapy regimen
      and potential cost-effectiveness analysis from the perspective of Canada's health care
      system; Evaluate the impact on activities of daily living as reflected by self-reported
      fatigue and pain using the FACT-Taxane and FACIT-Fatigue scores. In this study, the
      investigator will obtain oral consent using the prepared REB approved Consent Script. If the
      patient agrees to participate, the physician will dictate in the progress note they have had
      the above conversation with the patient. There will be no need for the patient to sign an
      informed consent form.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of performing a pragmatic clinical trial with an Integrated Consent Model.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Feasibility of performing this study will be measured with 2 composite endpoints: number of patients who received either TC-H or P-H chemotherapy compared to the number of participants who were approached to enter the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events/ toxicity profile between the two different approaches.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Toxicity profile (NCI CTC version 4.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of each chemotherapy regimen and potential cost-effectiveness analysis.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Health system cost of each chemotherapy regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Cost per one quality-adjusted life year (QALY) gained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Use of primary or secondary febrile neutropenia prophylaxis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as reflected by self-reported fatigue using FACIT-Fatigue scores.</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-Fatigue) scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as reflected by self-reported pain using FACT-Taxane scores</measure>
    <time_frame>up to 12 motnhs.</time_frame>
    <description>Functional Assessment of Cancer Therapy-Taxane Scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>TC-H Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel(P) + Trastuzumab(T)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-H x Paclitaxel (P) + Trastuzumab(T)</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Paclitaxel(P) + Trastuzumab(T)</arm_group_label>
    <arm_group_label>TC-H Chemotherapy</arm_group_label>
    <other_name>Docetaxel, Cyclophosphamide and Trastuzumab</other_name>
    <other_name>Paclitaxel and Trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HER-2 positive early stage breast cancer for whom TC-H or weekly P-H is
             being considered.

          -  Able to provide verbal consent.

          -  Willing to complete study related-questionnaires

        Exclusion Criteria:

          -  Unable to give informed consent or complete questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Fernandes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Fernandes, M.D.</last_name>
    <phone>1-519-685-8640</phone>
    <phone_ext>53267</phone_ext>
    <email>ricardo.fernandes@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morgan Black</last_name>
    <phone>1-519-685-8500</phone>
    <phone_ext>53213</phone_ext>
    <email>morgan.black@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Fernandes, M.D.</last_name>
      <phone>519-685-8640</phone>
      <email>ricardo.fernandes@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Black</last_name>
      <phone>519-685-8640</phone>
      <email>morgan.black@lhsc.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Ng, MD</last_name>
      <phone>613-737-7700</phone>
      <email>teng@toh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Ibrahim, MD</last_name>
      <phone>807-684-7200</phone>
      <email>ibrahimm@tbh.net</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Hantjis, MHSc</last_name>
      <phone>807-684-6639</phone>
      <email>hantjisa@tbh.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

